BioLine RX Ltd Company News
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new economic model data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – The Professional Society for Health Economics and Outcomes Research – 2024 conference,
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a poster presentation on apheresis center efficiency and CXCR4 antagonists including APHEXDA (motixafortide) in patients with multiple myeloma. The poster will be presented at the American Society for Apheresis (ASFA) 2024 Annual Meeting, taking place April 17-19, 2024, in Las Vegas, Nevada.
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has drawn-down the second tranche of $20 million under its previously announced $40 million non-dilutive debt financing agreement with funds and accounts managed by BlackRock.
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 7,500,000 of the Company's American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 7,500,000 ADSs, at a combined purchase price of
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript March 26, 2024 BioLineRx Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Fourth Quarter and Full Year 2023 Financial […]
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Since the 3Q:23 report in November, BioLineRx Ltd. (NASDAQ:BLRX) has been focused on Aphexda commercialization following drug approval in September 2023. Since then, two other trials evaluating motixafortide have dosed first patients. One was the gene therapy trial in collaboration with the Washington University School of
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its financial results for the year ended December 31, 2023, and provided recent corporate and portfolio updates.
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its audited financial results for the year ended December 31, 2023 on Tuesday, March 26, 2024, before the U.S. markets open.
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent, "Process for Manufacturing Peptide," covering a method of manufacturing motixafortide (BL-8040) that is suitable for large scale production.
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the first patient has been dosed in the randomized CheMo4METPANC Phase 2 combination clinical trial evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic c
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Subgroup Analyses of Genesis Trial Data at ASTCT & CIBMTR Washington University School of Medicine’s Zachary Crees, MD and BioLineRx’ (NASDAQ:BLRX) Ella Sorani, PhD descended on San Antonio, Texas last week to participate in poster presentations for the Transplantation & Cellular Therapy Meetings of the American
Old Arcived News About BioLine RX Ltd
- 7:03 am BioLineRx files a regulatory submission to commence a Phase 2 trial for BL-8040 for mobilization and collection of bone marrow stem cells.
- Bioline RX (BLRX) Stock Gains on Positive Test Results, Coverage Initiation.
- BioLineRx.
- BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results.
- BioLineRx and Major Global Pharmaceutical Company Form Strategic Collaboration for Screening and Development of Novel Drug Candidates. [at noodls] - - Global pharmaceutical company makes initial $10 million equity investment in BioLineRx - - BioLineRx to host conference call today, December, 16 at 10:00 a.m. EST - JERUSALEM--(BUSINESS WIRE)--Dec. 16, ...
- BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions. [at noodls] - Efficacy and safety study, in collaboration with MD Anderson Cancer Center, will assess BL-8040 as combination treatment with immunosuppressants Interim results of study, in patients with hypoplastic myelodysplastic ...
- BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization Treatment. [at noodls] - Study will be conducted in collaboration with , --(BUSINESS WIRE)--Dec. 14, 2015-- (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising ...
- BioLineRx Establishes Oncology Scientific Advisory Board. [at noodls] - TEL AVIV, Israel--(BUSINESS WIRE)--Dec. 3, 2015-- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic ...
- BIOLINERX LTD. Financials.
- BioLineRx Ltd. to Host Investor Breakfast in New York on December 3, 2015. [at noodls] - TEL AVIV, Israel--(BUSINESS WIRE)--Nov. 25, 2015-- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic ...
- BioLineRx Out-Licenses Novel Skin Lesion Treatment to Omega Pharma. [at noodls] - - Omega Pharma to develop and commercialize novel skin treatment for OTC use in Europe and additional selected countries - - First product expected to reach the market in 2016 - JERUSALEM--(BUSINESS WIRE)--Dec. ...
- BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform. [at noodls] - - Clinical trials in three additional indications for BL-8040 to be initiated in 2015 - - Development strategy presented today at BioLineRx investor meeting in New York - NEW YORK--(BUSINESS WIRE)--Dec. ...
- BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH Conference. [at noodls] - - Data show six-fold increase in mobilization of AML cells from bone marrow; Treatment with BL-8040 as single agent led to 70% decrease in AML cells in bone marrow and 3.5-fold increase in AML cell apoptosis ...
- BioLineRx Reports Third Quarter 2015 Financial Results. [at noodls] - TEL AVIV, Israel--(BUSINESS WIRE)--Nov. 16, 2015-- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic ...
- BioLineRx to Present at the LD Micro Main Event. [at noodls] - TEL AVIV, Israel--(BUSINESS WIRE)--Nov. 24, 2015-- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic ...
- BioLineRx to Report Third Quarter 2015 Results on November 16, 2015. [at noodls] - Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel--(BUSINESS WIRE)--Nov. 9, 2015-- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, ...
- Hedge Funds Are Selling Bioline RX Ltd.
BioLine RX Ltd Short Company Overview:
BioLineRx Ltd. is a biopharmaceutical development company. The Company develops clinical-stage therapeutic pharmaceutical drugs.
